Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Study uncovers proliferation of unapproved stem-cell procedures in US

04 July 2016

By James Brooks

Appeared in BioNews 858

The authors of a study detailing the rapid expansion of unlicensed stem-cell therapies in the US have called on the Food and Drug Administration (FDA) to act to stop thousands of patients being used as 'unwitting guinea pigs' for untested treatments.

In a study published in the journal Cell Stem Cell, Professor Paul Knoepfler and Dr Leigh Turner identify 351 companies marketing unapproved procedures at 570 clinics across the US.

While the majority of companies concerned offer stem-cell treatments for orthopaedic issues, at least 80 advertise stem-cell treatments for neurological diseases like Parkinson's and Alzheimer's diseases.

Dr Turner, an associate professor of bioethics at the University of Minnesota, said: 'Brakes ought to exist in a marketplace like this, but where are the brakes? Where are the regulatory bodies? And how did this entire industry come into being in a country where stem cell-based interventions and the medical devices that produce them are supposed to be regulated by the FDA?'

A decision from the US federal court in July 2012 effectively confirmed the FDA's authority to regulate stem-cell therapies in the same way as it does pharmaceuticals (see BioNews 667), but the regulatory guidelines it will use to police the sector are still being prepared. The FDA is due to have its next public hearing on the matter in September.

Dr Turner says that for about seven years now companies have been taking advantage of this regulatory void and 'making marketing assertions about stem cells treating 30–40 different diseases, and no one's taking meaningful regulatory action'.

Speaking to The Guardian, Dr Turner highlighted the 'pretty dramatic claims' of treatment for currently incurable diseases that his study uncovered, while in fact none of the procedures offered had been tested in clinical trials.

'In a way people are almost uninformed and unwitting guinea pigs,' he said. 'They are research subjects but no one is telling them that.'

The majority of clinics identified by the study offered treatments using the patients' own stem cells with no promise of any genetic modification. However, one business did offer treatments with induced pluripotent stem cells, another with embryonic stem cells, and two businesses offered stem cells from different animal species.

Professor Knoepfler, a stem-cell researcher at the University of California at Davis, said that his peers in stem-cell research should be concerned about the study's findings: 'There is a real risk that as clinics proliferate, if we don't address it in a more proactive way, as we see negative outcomes for patients grow and people get mixed bags of information about stem cells, then this could really negatively impact the public perception of this research.'

SOURCES & REFERENCES
UC Davis School of Medicine (press release) | 30 June 2016
 
Cell Stem Cell | 30 June 2016
 
The Guardian | 30 June 2016
 
Scientific American | 30 June 2016
 
Washington Post | 30 June 2016
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

20 March 2017 - by Caroline Casey 
The story of fetal-derived stem cells is explored in this documentary, from the ethics of how they're sourced and the clinical benefits some say they offer, to the barriers to licencing and their wider use...
19 September 2016 - by Dr Lucy Freem 
The US Food and Drug Administration has held a public hearing on proposals to regulate stem cell treatments in the same way as drugs...

21 September 2015 - by Paul Waldron 
The Food and Drug Administration must do more to control clinics offering unproven stem cell treatments in the USA, say scientists....
07 January 2013 - by Dr Linda Wijlaars 
Bone fragments were removed from the eyelid of a woman after a facelift that used her own stem cells yielded some unexpected results...
30 July 2012 - by Ruth Retassie 
A US federal court has ruled that a stem cell product is classified as a 'drug', falling under the jurisdiction of the Food and Drug Administration (FDA). The ruling allows the FDA to regulate stem cell therapy in the USA and could open clinics that offer stem cell treatments open to federal liability...
19 March 2012 - by Dr Sophie Pryor 
A cardiologist in Bonita Springs, Florida, USA, has had his medical licence suspended after allegedly performing an illegal stem cell treatment on a patient who died during the procedure...
09 January 2012 - by Oliver Timmis 
A professor of pathology and a midwife have been arrested in the US, charged with illegally supplying stem cells for unauthorised use. They are suspected of belonging to a team of at least four people who sold untested stem cell 'cures' to cancer patients and people with neurodegenerative diseases...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation